women with hypercholesterolemia received 25 g of soy protein or a placebo daily for 6 weeks, with treatment periods separated by 1 month. Markers of vascular inflammation were measured by enzyme-linked immunosorbent assay methods, including: soluble interleukin-2 receptor (sIL-2r), E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1). There was no effect of soy protein in comparison with placebo on the inflammatory markers: the sIL-2r level was 942.2 Ϯ 335.3 pg/mL with soy protein and 868.5 Ϯ 226.9 pg/mL with placebo (P ϭ .311); E-selectin was 39.6 Ϯ 16.5 ng/mL with soy protein and 42.1 Ϯ 17.6 ng/mL with placebo (P ϭ .323); P-selectin was 157.9 Ϯ 67.9 ng/mL with soy protein and 157.5 Ϯ 47.6 ng/mL with placebo, (P ϭ .977); ICAM-1 was 266.0 Ϯ 81.3 ng/mL with soy protein and 252.5 Ϯ 82.7 ng/mL with placebo (P ϭ .435); VCAM-1 was 402.7 Ϯ 102.1 ng/mL with soy protein and 416.4 Ϯ 114.8 ng/mL with placebo (P ϭ .53). Nitric oxide (NO), an important regulator of vascular homeostasis, is synthesized continuously in endothelial cells by the constitutive enzyme nitric oxide synthase (NOS III) from the substrate L-arginine. 1 NO plays an important role in vascular inflammation, and thus, affecting NO bioavailability may change vascular inflammation and the progression to atherosclerosis. 2 Many observational studies have found lower rates of coronary heart disease events in postmenopausal women who take hormone replacement therapy than in women not receiving this therapy. In the Lipid Research Clinics Program Follow Up Study, there was a 66% lower relative risk of death from cardiovascular disease in women who took hormone replacement than in women who did not. 3 In the Nurses' Health Study, 48,470 postmenopausal women were followed for as long as 10 years. There was a 44% lower risk for fatal and nonfatal cardiovascular events in women currently taking estrogen. 4 Estrogen significantly reduced levels of cell adhesion molecules E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) relative to respective pretreatment values, with the greatest effect noted with E-selectin. 5, 6 However, during an average follow-up period of 4.1 years of the Heart and Estrogen-progestin Replacement Study (HERS) trial, treatment with oral conjugated equine estrogens and medroxyprogesterone acetate did not reduce the overall rate of coronary heart disease events in postmenopausal women with established coronary disease. 7 Soybean foods contain a class of phytoestrogens known as isoflavons. There are 3 subclasses of isoflavones in soy foods (genistein, daidzein, and glycitein).
Conclusions
The evidence that natural isoflavones protect against several chronic diseases is both observational and experimental. In humans, epidemiologic findings clearly show a higher incidence of some common types of cancer (breast, prostate, and colon) and of coronary heart diseases in Western populations exposed to limited amounts of soybean isoflavons in the diet (genistein and daidzein). The antiestrogenic and estrogenic properties of isoflavons have been interpreted through an interaction of these molecules with true estrogen receptors. [8] [9] [10] As for the cardioprotective activity of isoflavons, it is well established that a soy diet decreases low-density lipoprotein cholesterol and total plasma cholesterol levels in both animals and humans.
11,12
Accordingly, we measured the effects of soy protein on markers of vascular inflammation in postmenopausal women with hypercholesterolemia in a randomized, double-blind, placebo-controlled study to determine whether soy protein has the same antiinflammatory effects as estrogens.
Methods
Women were randomly assigned dietary treatments of either 25 g of isolated isoflavones (Protein Technologies International, St Louis, Mo) or 25 g of total milk protein (Protein Technologies International), with each treatment period lasting 6 weeks and separated by 1 month in which the patients were off treatment. The only differences between the 2 products were the protein source and isoflavone content. All study participants returned to the hospital for blood drawing and brachial artery reactivity measurements at the end of each treatment period. Subjects were placed on a nitraterestricted diet (as high as 15 mg/day) for 3 days before each visit to reduce the contribution of dietary nitrates to serum nitrogen oxide levels. 13 The study was approved by the institutional review board of the hospital, and all participants gave written informed consent.
Laboratory assays
Blood samples for laboratory assays were obtained between 12 and 1 PM, after patients had a light breakfast, and the samples were immediately coded so that investigators performing laboratory assays would be blinded to subject identity or study sequence. Plasma and serum were separated by centrifugation and stored at Ϫ80°C until analysis. SIL-2R, E-selectin, P-selectin, ICAM-1, and VCAM-1 levels were measured by enzyme-linked immunosorbent assays (R&D Systems, Minneapolis, Minn).
Statistical analysis
Measurements are expressed as the mean Ϯ SD. The 2-sided paired Student t test was used to compare changes in laboratory values between soy protein and placebo treatments, with a P value Ͻ.05 considered to be an indicator of statistical significance. The primary study comparison predefined in advance of data collection was markers of vascular inflammation with soy protein treatment compared with those with a placebo.
Results
Thirty postmenopausal women with hypercholesterolemia (age 55 Ϯ 5 years) who had not taken hormone replacement, antioxidant vitamins, or lipid-lowering therapies in the preceding 2 months and who had low-density lipoprotein (LDL) cholesterol levels Ͼ130 mg/dL were enrolled in the study. All had plasma 17␤-estradiol levels Ͻ50 pg/mL and follicle stimulating hormone levels Ͼ50 pg/mL. No subject had hypertension or diabetes mellitus or was a current cigarette smoker. The baseline lipid profile levels were, total cholesterol 270.45 Ϯ 31.87 mg/dL, LDL cholesterol 178.5 Ϯ 28.5 mg/dL, high-density lipoprotein (HDL) cholesterol 60.42 Ϯ 17.78 mg/dL, and triglyceride 133.2 Ϯ 49.55 mg/dL. Treatment with all nonsteroidal anti-inflammatory agents (including aspirin) was discontinued during the study. Twenty-four study participants were compliant and took all the sachets that were given for the study and consumed a nitrate-restricted diet 3 days before each visit and measurement. Six women stopped the study in the first few days (4 women dropped out while they were taking the placebo and 2 women dropped out while they were taking soy protein) because of bad taste and nausea caused by the powder. Thus, 24 women completed both phases of the study and served as the source of data for this report.
Effects of soy protein on vascular inflammatory markers
There was no effect of soy protein in comparison with the placebo on the vascular inflammatory markers that were examined. The cell adhesion molecules (CAMs) that were studied are NO-dependent. The sIL-2r level was 942.2 Ϯ 335.3 pg/mL with soy protein and 868.5 Ϯ 226.9 pg/mL with placebo (P ϭ .311); the E-selectin level was 39.6 Ϯ 16.5 ng/mL with soy protein and 42.1 Ϯ 17.6 ng/mL with placebo (P ϭ .323); the P-selectin level was 157.9 Ϯ 67.9 ng/mL with soy protein and 157.5 Ϯ 47.6 ng/mL with placebo (P ϭ .977); the ICAM-1 level was 266.0 Ϯ 81.3 ng/mL on soy protein and 252.5 Ϯ 82.7 ng/mL with placebo (P ϭ .435); the VCAM-1 level was 402.7 Ϯ 102.1 ng/mL with soy protein and 416.4 Ϯ 114.8 ng/mL with placebo (P ϭ .53) ( Table I) . 
Effects of soy protein on cholesterol level

Discussion
The intake of soy protein (25 g daily for 6 weeks) did not affect markers of vascular inflammation in 24 postmenopausal women with hypercholesterolemia, compared with a placebo (milk protein). We focused on isolated soy protein containing naturally occuring isoflavones because of observational, epidemiologic, population-based studies that have demonstrated cardiac protection and antiatherogenic effects resulting from soybean isoflavones. "Dietary estrogens" are adsorbed from the intestinal tract, transported to the liver, and undergo an enterohepatic circulation. 14 The mechanisms through which isoflavones may exert the aforementioned effects seem to depend on their estrogen agonist/antagonist properties. Soy protein in the amount that we used (25 grams daily) has been shown to reduce total and LDL cholesterol levels in subjects with hypercholesterolemia. 15, 16 On the basis of these data, we reasoned that soy protein could have the same effects as estrogens on vascular inflammation in postmenopausal women. However, our results did not demonstrate anti-inflammatory effects. Our results could support the data presented in the HERS trial, with no demonstrated beneficial effects of estrogens given to postmenopausal women. Several groups have reported increases in NO synthase activity in endothelial cell cultures after incubation with physiologic concentrations of estradiol, an effect blocked by estrogen receptor inhibitors. [17] [18] [19] Increased NO bioactivity from estrogen administration may improve other important homeostatic properties of endothelium, such as inhibition of activation of proinflammatory genes. NO has been found to inhibit the activation of an important proinflammatory nuclear transcription factor, NFB. [20] [21] [22] In the presence of reduced cytosolic NO or increased cytosolic oxidant stress, NFB is activated by dissociation from its inhibitor subunit (IB) after IB phosphorylation in the cytosol. The heterodimer then translocates to the nucleus, where it binds to promotor regions of several proinflammatory genes, with transcription and synthesis of protein mediators of inflammation, including cytokines, chemokines, and cell adhesion molecules.
The pathophysiologic relevance of soluble cell adhesion molecules measured in human sera has been suggested by their localization in atherosclerotic plaques, 23, 24 their higher levels in patients with atherosclerosis compared with control subjects, [25] [26] [27] and their association with increased risk of myocardial infarction in apparently healthy subjects. 28 Serum concentrations of E-selectin, ICAM-1, and VCAM-1 were reported to be higher in postmenopausal women with coronary artery disease who were not taking hormone therapy than in postmenopausal women with coronary artery disease who were taking hormone therapy at the time of cardiac catheterization. 29 It has been reported that estrogen significantly reduced levels of the cell adhesion molecules E-selectin, ICAM-1, and VCAM-1 compared with respective pretreatment values, with the greatest effect noted with E-selectin, the cell adhesion molecule specific to the activated endothelium. 6 It has been demonstrated that raloxifene (a selective estrogen receptor modulator) also significantly reduced levels of E-selectin and ICAM-1 relative to placebo values, but had no effect on VCAM-1. 5 
Study limitations
A possible explanation for failure to demonstrate an effect of soy protein is that the dose used in our study (25 g daily for 6 weeks) was insufficient. However, we did not want to use higher doses, because we wanted to prevent any possible adverse effects, and several studies (including this study) have reported an effect on the lipid profile with that amount.
Levels of asymmetric dimethylarginine were not measured in the plasma of our participants. Thus, it is possible that had levels of asymmetric dimethylarginine been found to be low in our patients, improvement in markers of vascular inflammation with soy protein would have been expected.
The sample size was small, and with a sample size of 24 in a crossover design study and continuous out- comes, power calculations can determine the minimal detectable effect with 80% power. This effect is expressed as a standardized effect size (%SD), so it can be extrapolated across te various outcomes. A much larger study would have found differences of this magnitude to be statistically significant.
Summary
We found that soy protein did not affect markers of vascular inflammation in postmenopausal women with mild hypercholesterolemia. Further and longer studies with different doses of soy protein should be conducted in a double-blind, placebo-controlled manner and in different populations.
